Bluebird Bio

Bluebird Bio CEO Nick Leschly

The biotech: Bluebird Bio
Round: $60 million
Based: Cambridge, MA
CEO: Nick Leschly
Investors: ARCH Venture Partners, Forbion Capital Partners, RA Capital Management, Third Rock Ventures,TVM Capital, Undisclosed Investor, Undisclosed Investor

The scoop: Whatever disadvantages Bluebird may face, lack of cash isn't one of them. This most recent round brought its venture take to $110 million, making it one of the better-funded biotechs in early-stage development. Bluebird, though, is focused on rare diseases, where small studies can deliver big results. The Third Rock creation--CEO Nick Leschly was part of the Millennium mafia that booted up the venture group--has already scored proof-of-concept data for adrenoleukodystrophy, or ALD. And Leschly now has his sights set on a pivotal study for next year. Bluebird is the reincarnation of Genetix, a repurposed gene therapy company that believes the technology's time has finally come. Bluebird was named a Fierce 15 company this year.

For more:
Special Report: Bluebird Bio – 2012 Fierce 15
Bluebird adds $60M venture haul to fuel pivotal gene therapy study
Bluebird's gene therapy song attracts $30M venture round

Bluebird Bio

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.